Maravai Lifesciences Holdings Inc. (MRVI)
3 Struggling Stocks Down More Than 50% This Year That Look Cheap But Come With Plenty of Risk
The stock market is in a bit of a tailspin of late as investors worry about the future of the economy. It can be a great idea to buy stocks on weakness if you're investing for the long term, but that doesn't mean that every struggling stock is going to recover.
Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2024 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Deb Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - EVP and Chief Financial Officer Drew Burch - President, Nucleic Acid Production Conference Call Participants Dan Leonard - UBS Justin Bowers - Deutsche Bank Yuko Oku - Morgan Stanley Matt Hewitt - Craig-Hallum Dan Arias - Stifel Operator Good afternoon, ladies and gentlemen, and welcome, everyone, to the Maravai LifeSciences Third Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2024 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2024 Results Conference Call August 7, 2024 5:00 PM ET Company Participants Deborah Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Tejas Savant - Morgan Stanley Matt Hewitt - Craig-Hallum Justin Bowers - Deutsche Bank Conor McNamara - RBC Capital Markets Michael Ryskin - Bank of America Matt Larew - William Blair Kyle Crews - UBS Operator Thank you for standing by and welcome to the Maravai LifeSciences Second Quarter 2024 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Maravai (MRVI) Advances in RNA Research With New Collaboration
Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.
